-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
Latest News
-
Vico’s Trial Adjusts With Twice-Yearly Dosing, And The U.S. Is Next
⏱️ 6 min read | Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested just twice a year, and the FDA has cleared the way for US trials to begin later this year.
-
HD Therapeutics Conference 2012 Updates: Day 1
Day 1 of our coverage of the Huntington's Disease Therapeutics Conference
-
Coming soon: HD Therapeutics Conference 2012
Huntington's Disease Therapeutics Conference starts next week. Twitter follow @HDBuzzfeed for live updates!
-
New analysis suggests 'small' CAG length doesn't matter after all
Size isn't everything: new research suggests that only a person's big CAG count, not the small one, affects HD onset
-
Special 'brain fat' injection helps HD mice
Directly injecting the brains of HD mice with a good type of fat called ganglioside GM1 provides dramatic benefit
-
HDYO! Huntington's Disease Youth Organization goes live
The Huntington's Disease Youth Organization website has just launched and its website is now active at www.hdyo.org
-
Could mesenchymal stem cells deliver gene silencing drugs?
Stem cells can deliver HD gene silencing drugs into cells in a dish. Do we need another delivery technology?
-
Double success for huntingtin RNAi gene silencing
2 bits of good news for RNAi gene silencing in HD: it's safe over six months, and a way to treat bigger brain areas
-
New experiments clarify the role of SIRT1 in HD – or do they?
Work from multiple labs suggests activating a protein called SIRT1 might help HD, but the picture is still confusing
-
Bone marrow transplantation in Huntington's Disease
Bone marrow transplant protects HD mice from some symptoms, suggesting the immune system may be an important target
-
2011 – a year in Huntington's disease research
Looking back at a year in Huntington's disease research – and the first year of HDBuzz
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
